Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 May to Question 86 on Prostate Cancer, what assessment his Department has made of the NHS’s readiness for using lutetium vipivotide tetraxetan in the treatment of prostate-specific membrane antigen positive metastatic castration-resistant prostate cancer.

The National Institute for Health and Care Excellence (NICE) is the independent body which makes recommendations for the National Health Service on the clinical and cost effectiveness of new medicines. NICE is currently appraising lutetium vipivotide tetraxetan for the treatment of prostate-specific membrane antigen-positive castration-resistant metastatic prostate cancer. If recommended, it will be eligible for funding and available to National Health Service patients through the Cancer Drugs Fund on publication of NICE’s draft guidance. It expected to published in autumn 2022.